Apellis Pharmaceuticals, INC. (APLS) — 8-K Filings

8-K Filings (10)

• Apellis Pharmaceuticals Enters Material Definitive Agreement — Jul 1, 2025 Risk: medium
  On July 1, 2025, Apellis Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature or terms of this a
• Apellis Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 4, 2025 Risk: low
  Apellis Pharmaceuticals, Inc. filed an 8-K on June 4, 2025, reporting on matters submitted to a vote of security holders as of June 3, 2025. The filing does not
• Apellis Pharmaceuticals Announces Board and Executive Changes — Apr 21, 2025 Risk: medium
  On April 17, 2025, Apellis Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fi
• Apellis Pharmaceuticals Names New Chief Medical Officer — Jan 13, 2025 Risk: medium
  Apellis Pharmaceuticals, Inc. announced on January 8, 2025, the departure of its Chief Medical Officer, Dr. Federico Cervera, effective January 10, 2025. The co
• Apellis Pharmaceuticals Files 8-K Report — Aug 8, 2024 Risk: low
  On August 8, 2024, Apellis Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details
• Apellis Pharmaceuticals Files 8-K on Shareholder Votes — Jun 5, 2024 Risk: low
  Apellis Pharmaceuticals, Inc. filed an 8-K on June 5, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specif
• Apellis Pharmaceuticals Enters Material Agreement — May 14, 2024 Risk: medium
  On May 13, 2024, Apellis Pharmaceuticals, Inc. entered into a Material Definitive Agreement and created a direct financial obligation. The filing does not speci
• Apellis Files 8-K on Financials and Other Events — Feb 27, 2024 Risk: low
  Apellis Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, to report on its "Results of Operations and Financial Condition," "Other Events," and "Financia
• Apellis Pharma Reports Executive Changes & Comp Arrangements — Jan 22, 2024
  Apellis Pharmaceuticals, Inc. filed an 8-K on January 22, 2024, reporting events from January 16, 2024, related to changes in its executive team and compensatio
• Apellis Pharma Files 8-K on Operations & Financial Condition — Jan 8, 2024
  Apellis Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing indicates that the co

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX